Life Sciences & MOB Investment Surge Amidst Broader CRE Headwinds
By Majid Radaei, RadCRE · · Industry Insights
Despite broader CRE slowdowns, life sciences and medical office building (MOB) sectors are demonstrating robust investor demand and resilient fundamentals, with Q1 2026 transaction volumes signaling continued growth.
Resilient Demand Drives Life Sciences and MOB Investment
In a commercial real estate landscape marked by fluctuating interest rates and re-evaluation of valuation metrics across traditional asset classes, the life sciences and medical office building (MOB) sectors continue to exhibit remarkable resilience and attract significant institutional capital. These sectors, largely driven by demographic shifts, technological advancements in healthcare, and sustained R&D spending, have decoupled from some of the cyclical pressures impacting other property types.
According to recent reports, investment in life sciences properties, encompassing lab, R&D, and manufacturing facilities, remained strong through early 2026. While transaction volume for CRE overall dipped, specialized sectors like life sciences saw sustained capital deployment. Major players like Blackstone have continued their strategic investments, notably focusing on their BioMed Realty platform, which currently manages a portfolio valued in the tens of billions across key life science clusters such as Boston-Cambridge, San Francisco Bay Area, and San Diego. Green Street Advisors data indicates that life science property values have largely held firm or seen only minor adjustments compared to more significant declines in office assets.
Key Drivers Fueling Sector Growth
The demand for life sciences real estate is intrinsically linked to substantial R&D expenditure by pharmaceutical and biotechnology companies. The National Institutes of Health (NIH) budget, a key indicator, has seen consistent increases, providing a stable foundation for research and development activities that require specialized lab space. Additionally, venture capital funding into biotech startups, though somewhat moderated from its 2021 peaks, remains robust, underpinning the creation and expansion of companies needing state-of-the-art facilities.
Similarly, the MOB sector benefits from an aging population requiring more healthcare services and a shift towards outpatient care, reducing reliance on expensive hospital stays. Private equity firms and institutional investors, recognizing the stable income streams and recession-resistant nature of MOBs, continue to chase these assets. Recent transactions underscore this trend, such as the sale of a portfolio of MOBs in the Sun Belt region for an aggregate of over $200 million in Q4 2025, reflecting cap rates often in the 5.5% to 6.5% range for high-quality, long-leased properties. These cap rates illustrate the premium investors are willing to pay for healthcare-anchored assets compared to general office properties experiencing cap rate expansion.
Financing Landscape and Investor Outlook
The financing environment for life sciences and MOB assets remains relatively robust compared to other property types. Lenders view these specialized assets favorably due to their essential nature and strong tenancy. While overall lending standards have tightened, institutional lenders and debt funds are still active in this space. Construction financing for new lab development, particularly in undersupplied markets like Boston's Seaport District or San Diego's Torrey Pines, continues, albeit with more stringent equity requirements. Existing MOBs with strong credit tenants and long lease terms are attracting competitive loan-to-value ratios.
RadCRE Perspective
Majid Radaei, Founder of RAD Commercial Realty, notes, "The divergence in performance between life sciences/MOB and traditional office space is not a temporary anomaly but a fundamental repricing driven by underlying demand and risk profiles. While cap rates for general office assets have expanded significantly, often by 100-150 bps or more over the past 18 months, high-quality MOBs and purpose-built lab facilities have seen much more contained cap rate shifts, perhaps 25-50 bps, if any. This reflects the defensive nature of these assets.
For our clients at RadCRE, this translates into a clear strategy: identify opportunities in value-add life science conversions, especially in secondary markets with emerging academic and research clusters, or acquire well-located, quality MOBs with strong tenant anchors that present stable cash flows. On the financing side, while CMBS spreads for life sciences can range from T+175 to T+250 bps for stabilized assets, RadCRE is strategically leveraging relationships with relationship-focused bank and debt fund lenders who understand the nuances of these properties. For ground-up lab developments, non-recourse construction financing remains challenging, but we've successfully structured pref equity and mezzanine debt solutions, sometimes priced at 14-17%, to bridge the capital stack for well-capitalized developers in prime locations where the long-term fundamentals are undeniable."
The long-term outlook for life sciences and MOB real estate remains positive, driven by non-discretionary spending and an evolving healthcare landscape. Investors are increasingly seeking defensive, high-growth alternatives within their portfolios, positioning these sectors for continued strong performance.
Tags: life sciences real estate, medical office building investment, CRE investment trends, RadCRE, healthcare real estate, property values, commercial real estate financing
Sources: Blackstone earnings reports, Green Street Advisors, CoStar, Real Capital Analytics, Commercial Observer, JLL Research